|Awarded On||February 16, 2022|
|Title||Overcoming liver toxicity of anti-CD137 cancer immunotherapy|
|Award Mechanism||Individual Investigator|
|Institution/Organization||The University of Texas Health Science Center at San Antonio|
|Principal Investigator/Program Director||Alexei Tumanov|
|Cancer Sites||All Sites|
Novel antibody-based immunotherapies for cancer are having major clinical impact. However, accompanying immune-mediated adverse reactions, such as liver toxicity, remain the major obstacle of these therapies. Costimulatory molecule called CD137 is a powerful target for immunotherapy. Unfortunately, clinical trials of anti-CD137 antibody (Urelumab) in patients with advanced cancers revealed dramatic liver toxicity. Therefore, overcoming liver toxicity, a major roadblock of anti-CD137 and other checkpoint molecule targeted therapies is crucial.
Our preliminary data identified an immune molecule, called lymphotoxin beta receptor (LTbR) as a critical regulator of anti-CD137 antibody induced hepa...